Furthermore , improvements greater than or equal to the minimum clinically important difference were more frequently reported by tofacitinib-treated patients versus placebo for PtGA ( P < 0.05 ) , pain ( P < 0.0001 ) , HAQ DI ( P < 0.05 ) , SF-36v2 physical and mental component summary scores ( P < 0.05 ) , and FACIT-F ( P < 0.001 for 5 mg twice daily ) .